RESUMEN
Candida spp. are an important cause of nosocomial bloodstream infections. Currently, complete identification of yeasts with conventional methods takes several days. We report here the first evaluation of an extraction method associated with the Vitek MS matrix-assisted laser desorption ionization time of flight mass spectrometry for direct identification of Candida species from positive blood cultures. We evaluated this protocol with blood cultures that were inoculated with reference and routine isolates (eight reference strains, 30 patients isolates and six mixed cultures containing two strains of different Candida species), or from patients with candidemia (28 isolates). This method performed extremely well (97% correct identification) with blood cultures of single Candida spp. and significantly reduced the time of diagnosis. Nevertheless, subculture remains indispensable to test fungal resistance and to detect mixed infections.
Asunto(s)
Candida/química , Candida/clasificación , Candidemia/diagnóstico , Técnicas Microbiológicas/métodos , Micología/métodos , Manejo de Especímenes/métodos , Espectrometría de Masa por Láser de Matriz Asistida de Ionización Desorción/métodos , Sangre/microbiología , Candida/aislamiento & purificación , Humanos , Sensibilidad y Especificidad , Factores de TiempoRESUMEN
We assessed the ability to early detect a toxoplasmic seroconversion between 1 immunoblot (LDBIO II®) and 6 automated assays (TGS TA®, Architect®, Vidas II®, Liaison II®, Platelia®, and Elecsys®), comparing the time before anti-Toxoplasma gondii IgG detection during infection in pregnant women. From 2007 to 2015, 620 sera of 269 women were included. The median durations before positive IgG detection with Vidas II®, Liaison II®, Platelia®, and Elecsys® were significantly longer than Architect® with differential times from 11 to 28days (P<0.001). This time was significantly shortened by the use of LDBIO®, resulting in a saving of 13days (P<0.001). The detection of a positive rate of IgG with TGS TA® was as early as Architect® (P=0.105). The ability to early detect a toxoplasmic seroconversion is not equivalent between the assays and has to be considered when selecting the reagents to reduce the time to therapeutic intervention.